Advertisement
GSK vs MRK
Which Stock Would AI Choose? GlaxoSmithKline (GSK) vs. Merck (MRK) Stock Comparison
Key Takeaways
- GlaxoSmithKline (GSK) delivered Q2 2026 results with 5% sales growth at constant exchange rates and 7% core operating profit growth, driven by specialty medicines.
- Merck (MRK) has shown stronger year-to-date momentum compared to GSK in recent market activity, benefiting from its dominant oncology portfolio.
- GSK shares traded near $51–52 in late July 2026, reflecting rangebound behavior amid pipeline updates and strategic initiatives.
- MRK maintains a larger market capitalization and higher relative performance over the past year versus GSK.
- Both companies operate in the pharmaceuticals sector with exposure to regulatory and clinical development risks.
- Market sentiment for GSK has been shaped by earnings beats offset by one-off factors, while MRK benefits from established product leadership.
Introduction
GlaxoSmithKline (GSK) and Merck (MRK) represent two established players in the global pharmaceuticals industry, offering investors exposure to drug development, vaccines, and specialty treatments. This comparison examines their recent stock performance, business drivers, and market positioning in the current environment. Traders and investors focused on sector rotation, relative value, and AI-driven trend analysis may find this overview useful for evaluating portfolio allocations between these large-cap healthcare names.
GSK Overview and Recent Performance
GlaxoSmithKline (GSK) is a global biopharmaceutical company focused on specialty medicines, vaccines, and general medicines. In recent weeks, the company reported second-quarter 2026 results showing sales of £8.4 billion, up 5% at constant exchange rates, with core operating profit rising 7% and core earnings per share increasing 9%. Shares have traded in a range near $51–52, posting modest year-to-date gains around 5% while experiencing slight declines over the prior 30 days amid mixed pipeline news and strategic updates. Recent market activity has reflected investor digestion of oncology pipeline developments and upcoming catalysts, keeping sentiment measured.
MRK Overview and Recent Performance
Merck (MRK) is a leading pharmaceutical company with a strong emphasis on oncology, vaccines, and animal health. Over recent weeks, the stock has demonstrated relative outperformance compared with peers in the sector, supported by its established product portfolio and consistent revenue streams. Year-to-date returns have exceeded those of GlaxoSmithKline (GSK), with shares trading around $130 levels amid broader market rotations. Performance has been influenced by ongoing clinical advancements and stable demand for key therapies, contributing to steadier price behavior in the current environment.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the platform’s highest-ranked AI trading bots from a pool of several hundred available across hundreds of tickers. Only the most suitable bots for prevailing market conditions earn placement in this section, with selections drawn from 298 to 351 total robots depending on the period. Available bots exhibit varied trading styles, strategies, timeframes, and performance metrics, including reported returns up to +241% and win rates in the 70–80% range in select backtested scenarios. Users can explore different risk profiles and ticker exposures to identify bots aligned with their objectives. Visit the Trending AI Robots page to review current selections.
Head-to-Head Comparison
GlaxoSmithKline (GSK) and Merck (MRK) differ in scale and focus: GSK emphasizes specialty medicines and vaccines with recent pipeline acceleration efforts, while MRK maintains leadership in oncology through established blockbusters. In recent market activity, MRK has delivered stronger relative returns year-to-date compared with GSK’s more modest gains. Both face sector risks including clinical trial outcomes, regulatory approvals, and pricing pressures. GSK’s recent earnings showed growth in core metrics but were partly supported by one-off items, whereas MRK benefits from more predictable revenue visibility. Market sentiment favors MRK’s positioning for stability, while GSK offers potential upside tied to upcoming strategic events and diversification.
Tickeron AI Verdict
Based on observable factors such as trend consistency and relative positioning in recent market activity, Tickeron’s AI would currently favor Merck (MRK) over GlaxoSmithKline (GSK) with moderate probability. MRK’s stronger momentum and established catalysts provide a more stable profile compared with GSK’s rangebound behavior amid mixed developments. This assessment reflects probabilistic evaluation of available data rather than guarantees of future outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Hold and MRK is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 0 FA rating(s) are green whileMRK’s FA Score has 2 green FA rating(s).
- GSK’s FA Score: 0 green, 5 red.
- MRK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 3 TA indicator(s) are bullish while MRK’s TA Score has 4 bullish TA indicator(s).
- GSK’s TA Score: 3 bullish, 6 bearish.
- MRK’s TA Score: 4 bullish, 4 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а -5.65% price change this week, while MRK (@Pharmaceuticals: Major) price change was +5.65% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.23%. For the same industry, the average monthly price growth was +0.30%, and the average quarterly price growth was +2.34%.
Reported Earning Dates
GSK is expected to report earnings on Oct 28, 2026.
MRK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.23% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| GSK | MRK | GSK / MRK | |
| Capitalization | 98.2B | 335B | 29% |
| EBITDA | 9.68B | 19.4B | 50% |
| Gain YTD | 3.648 | 30.943 | 12% |
| P/E Ratio | 15.57 | 108.67 | 14% |
| Revenue | 33.2B | 65.8B | 50% |
| Total Cash | N/A | N/A | - |
| Total Debt | N/A | 49.1B | - |
GSK | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 60 | 45 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 39 Fair valued | 61 Fair valued | |
PROFIT vs RISK RATING 1..100 | 45 | 40 | |
SMR RATING 1..100 | 35 | 47 | |
PRICE GROWTH RATING 1..100 | 56 | 9 | |
P/E GROWTH RATING 1..100 | 62 | 2 | |
SEASONALITY SCORE 1..100 | 65 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GSK's Valuation (39) in the Pharmaceuticals Major industry is in the same range as MRK (61). This means that GSK’s stock grew similarly to MRK’s over the last 12 months.
MRK's Profit vs Risk Rating (40) in the Pharmaceuticals Major industry is in the same range as GSK (45). This means that MRK’s stock grew similarly to GSK’s over the last 12 months.
GSK's SMR Rating (35) in the Pharmaceuticals Major industry is in the same range as MRK (47). This means that GSK’s stock grew similarly to MRK’s over the last 12 months.
MRK's Price Growth Rating (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (56). This means that MRK’s stock grew somewhat faster than GSK’s over the last 12 months.
MRK's P/E Growth Rating (2) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (62). This means that MRK’s stock grew somewhat faster than GSK’s over the last 12 months.
| GSK | MRK | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 57% |
| Stochastic ODDS (%) | 2 days ago 59% | 2 days ago 56% |
| Momentum ODDS (%) | 2 days ago 45% | 2 days ago 60% |
| MACD ODDS (%) | 2 days ago 44% | 2 days ago 54% |
| TrendWeek ODDS (%) | 2 days ago 53% | 2 days ago 57% |
| TrendMonth ODDS (%) | 2 days ago 49% | 2 days ago 56% |
| Advances ODDS (%) | 9 days ago 62% | 2 days ago 57% |
| Declines ODDS (%) | 4 days ago 54% | 17 days ago 51% |
| BollingerBands ODDS (%) | 2 days ago 41% | 2 days ago 48% |
| Aroon ODDS (%) | 2 days ago 66% | 2 days ago 63% |
Advertisement
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with NVS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then NVS could also see price increases.